Harbour BioMed and Bristol Myers Squibb (BMS) have entered into a multi-year, worldwide strategic partnership and licensing agreement focused on the development of multi-specific antibodies. This collaboration is set to leverage Harbour BioMed’s proprietary antibody discovery platform alongside BMS’s extensive expertise in drug development and commercialization.
The partnership underscores the growing trend in the biopharmaceutical industry towards innovative therapeutic modalities that can address complex diseases more effectively. By combining their strengths, both companies aim to enhance their portfolios and expedite the delivery of novel treatments to patients.
This agreement not only reflects the increasing importance of multi-specific antibodies in therapeutic strategies but also highlights the competitive landscape where collaboration is becoming essential for advancing drug development. As companies seek to optimize their resources and capabilities, such partnerships may pave the way for breakthroughs in treatment options and improved patient outcomes.
Start your 7-day trial and see what the database can do →
